Specific features of ß-catenin-mutated hepatocellular carcinomas

IF 6.4 1区 医学 Q1 ONCOLOGY British Journal of Cancer Pub Date : 2024-09-11 DOI:10.1038/s41416-024-02849-7
Camille Dantzer, Lydia Dif, Justine Vaché, Sara Basbous, Clotilde Billottet, Violaine Moreau
{"title":"Specific features of ß-catenin-mutated hepatocellular carcinomas","authors":"Camille Dantzer, Lydia Dif, Justine Vaché, Sara Basbous, Clotilde Billottet, Violaine Moreau","doi":"10.1038/s41416-024-02849-7","DOIUrl":null,"url":null,"abstract":"<p><i>CTNNB1</i>, encoding the ß-catenin protein, is a key oncogene contributing to liver carcinogenesis. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer in adult, representing the third leading cause of cancer-related death. Aberrant activation of the Wnt/ß-catenin pathway, mainly due to mutations of the <i>CTNNB1</i> gene, is observed in a significant subset of HCC. In this review, we first resume the major recent advances in HCC classification with a focus on <i>CTNNB1</i>-mutated HCC subclass. We present the regulatory mechanisms involved in β-catenin stabilisation, transcriptional activity and binding to partner proteins. We then describe specific phenotypic characteristics of <i>CTNNB1</i>-mutated HCC thanks to their unique gene expression patterns. <i>CTNNB1</i>-mutated HCC constitute a full-fledged subclass of HCC with distinct pathological features such as well-differentiated cells with low proliferation rate, association to cholestasis, metabolic alterations, immune exclusion and invasion. Finally, we discuss therapeutic approaches to target ß-catenin-mutated liver tumours and innovative perspectives for future drug developments.</p>","PeriodicalId":9243,"journal":{"name":"British Journal of Cancer","volume":null,"pages":null},"PeriodicalIF":6.4000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41416-024-02849-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

CTNNB1, encoding the ß-catenin protein, is a key oncogene contributing to liver carcinogenesis. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer in adult, representing the third leading cause of cancer-related death. Aberrant activation of the Wnt/ß-catenin pathway, mainly due to mutations of the CTNNB1 gene, is observed in a significant subset of HCC. In this review, we first resume the major recent advances in HCC classification with a focus on CTNNB1-mutated HCC subclass. We present the regulatory mechanisms involved in β-catenin stabilisation, transcriptional activity and binding to partner proteins. We then describe specific phenotypic characteristics of CTNNB1-mutated HCC thanks to their unique gene expression patterns. CTNNB1-mutated HCC constitute a full-fledged subclass of HCC with distinct pathological features such as well-differentiated cells with low proliferation rate, association to cholestasis, metabolic alterations, immune exclusion and invasion. Finally, we discuss therapeutic approaches to target ß-catenin-mutated liver tumours and innovative perspectives for future drug developments.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ß-catenin突变肝细胞癌的特殊特征
编码ß-catenin蛋白的CTNNB1是导致肝癌发生的关键癌基因。肝细胞癌(HCC)是成人原发性肝癌中最常见的一种,是癌症相关死亡的第三大原因。Wnt/ß-catenin通路的异常激活,主要是由于CTNNB1基因的突变,在相当一部分HCC中被观察到。在这篇综述中,我们首先回顾了最近在 HCC 分类方面取得的主要进展,重点关注 CTNNB1 基因突变的 HCC 亚类。我们介绍了参与β-catenin稳定、转录活性和与伙伴蛋白结合的调控机制。然后,我们描述了 CTNNB1 突变的 HCC 的特殊表型特征,这些特征得益于其独特的基因表达模式。CTNNB1突变型HCC是HCC的一个完整亚类,具有独特的病理特征,如细胞分化好且增殖率低、与胆汁淤积有关、代谢改变、免疫排斥和侵袭。最后,我们讨论了针对ß-catenin突变肝肿瘤的治疗方法以及未来药物开发的创新前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
British Journal of Cancer
British Journal of Cancer 医学-肿瘤学
CiteScore
15.10
自引率
1.10%
发文量
383
审稿时长
6 months
期刊介绍: The British Journal of Cancer is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research.It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention,diagnosis and treatment.
期刊最新文献
Cardiotoxicity following thoracic radiotherapy for lung cancer. Low-dose arsenic trioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer. Perioperative safety of risk-reducing mastectomy. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1